HARBIN, China, Sept. 10 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it successfully developed 26 new drugs that are currently in clinical trials.
Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), a wholly-owned
subsidiary of China Sky One Medical, recently completed research and
development for the 26 new drugs, which have been submitted to the State
Food and Drug Administration (SFDA) in the PRC for approval.
-- Four drugs, including Cleaning suppositories, Tinidazole
suppositories, Policresulen vaginal suppositories, and Aciclover gel
are for the treatment of vaginits;
-- Three drugs, including Chlorhexidine Gluconate, Cetylpyridinium
Chloride and Compound Chlorhexidine, are gargles for the treatment
-- Three drugs, including Diclofenac Sodium Suppositories, Paediatric
Ibuprofen suppositories and Musky cream, are for pain relief;
-- Three drugs, including Hydroxybenzene gel, Podophyllotoxin Tincture
and Nitrofurantoin suppositories, are anti-infectives;
-- Two drugs, including Collunarium and Compound Naphazoline Spray, are
for the treatment of rhinopathy;
-- Two drugs, including Sulfasalazine suppositories and Sodium ferulate
injection are for the treatment of cardiovascular disease;
-- Methionine Vitamin B1 injection is for improving liver function;
-- Doxofylline injection is for the treatment of asthma;
-- Pantoprazole sodium injection is for the treatment of
|SOURCE China Sky One Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved